Trial results

$RNAC — Descartes-08

Cartesian Therapeutics, Inc. (RNAC) Descartes-08: trial results in Generalized myasthenia gravis, 2027.

Research by Catalyst Intel

The catalyst

"Cartesian remains on track to readout topline data from its Phase 3 AURORA trial of Descartes-08 in MG in the first quarter of 2027, with a BLA filing expected in mid-2027."

— Cartesian Therapeutics, 8-K filed 2026-09-29 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.

Event id

RNAC-DESCARTES08-2026

Company

Cartesian Therapeutics, Inc.

Kind

Trial results

Indication

Generalized myasthenia gravis

Window

2027-01-01 – 2027-12-31

Status

slate

The bar

No bar has been published for this event yet.

Verdicts

Sealed with the bar. Any verdict for this event reaches this page on 2028-01-30; subscribers get it on the day.